The objective of this work was to develop and characterise an amikacin sulfate loaded emulgel to be used as a co-adjuvant treatment for mycetoma caused by principal agents Actinomadura madurae and Nocardia brasiliensis. Development of the amikacin sulfate emulgel was conducted in 3 stages: (1) formulation of the emulsion containing amikacin; (2) selection of the proportion of pluronic F-127 necessary to form a gel; and (3) formation of the emulgel. The emulgel was characterised by the values of pH, relative density, accelerated stability, viscosity, extensibility, adhesiveness, cumulative amount of amikacin, and skin permeation (k_p and flux). The proportion of emulsifiers in the emulsion was 10% and 0.77% (w/w) of amikacin, and the emulsion was stable when subjected to the centrifugal test. Agel with 30% pluronic F-127 and an average adhesiveness of 2.7 mJ was used to form the emulgel. The formulated amikacin sulfate emulgel has the following properties: pH 5.5; relative density, 0.907; accelerated stability (centrifugation); extensibility. 923.72 mm²; adhesiveness, 1.27 mJ; cumulative amikacin (within 24 h), 34.13%; F = 105 μg/cm²/h; k_p = 0.016 cm/h; and t_Lag = 14.75 h. The emulgel formulation contains 0.77% of amikacin and demonstrates appropriate technical characteristics to be used as a complement to systemic administration for the treatment of mycetoma.

这项工作的目的是开发和表征载有硫酸丁胺卡那霉素的乳胶，以用作主要药物马氏猕猴桃和巴西诺卡氏菌引起的真菌病的辅助治疗。硫酸丁胺卡那霉素乳剂的开发分三个阶段进行：（1）配制含丁胺卡那霉素的乳液；（2）选择形成凝胶的普卢尼克F-127的比例；（3）乳胶的形成。乳胶的特征在于pH值，相对密度，加速稳定性，粘度，延展性，粘附性，丁胺卡那霉素的累积量和皮肤渗透性（k _p和流量）。乳化剂中乳化剂的比例为阿米卡星的10％和0.77％（w / w），并且在进行离心测试时该乳化剂是稳定的。使用具有30％普朗尼克F-127和平均粘附力为2.7 mJ的Agel形成乳胶。配制的硫酸阿米卡星乳化凝胶具有以下性能：pH 5.5； pH 5.5。相对密度0.907；加速稳定性（离心）；可扩展性。923.72毫米² ; 粘附力1.27 mJ; 累积丁胺卡那霉素（24小时内），占34.13％；F = 105μg/ cm ² / h；k _p＝ 0.016cm / h；和t_滞后= 14.75小时。该乳剂制剂含有0.77％的丁胺卡那霉素，并显示出适当的技术特性，可作为全身给药的补充剂用于治疗菌丝瘤。